COVID-19 vaccine clinical development was conducted with unprecedented speed.
Immunity measurements were concentrated on the antibody response which left significant …

Objectives Immunocompromised patients were excluded from COVID-19 vaccine clinical
trials. The objectives of the study were to measure antibody responses, levels, and …

There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate
the growing economic crisis that has ensued from societal lockdown. Vaccines are being …

SARS-COV-2 vaccines have been shown to be efficacious primarily in healthy volunteer
populations and population level studies. Immune responses following SARS-CoV-2 …

The novel SARS-CoV-2 is a recently emerging virus causing a human pandemic. A great
variety of symptoms associated with COVID-19 disease, ranging from mild to severe …

SARS-CoV-2-specific T cell response has been proven essential for viral clearance, COVID-
19 outcome and long-term memory. Impaired early T cell-driven immunity leads to a severe …

Severe disease due to COVID-19 has declined dramatically as a result of widespread
vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 …

While the immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID‐
19) has been characterized in several well-conducted clinical trials, real-world evidence …

Understanding immune reactivity against SARS-CoV-2 is essential for coping with the
COVID-19 pandemic. Herein, we discuss experiences and open questions about the …

Abstract Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from …